Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3928477

CCCCNCCCC.O=C(O)C(F)(F)F

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FUCA1 P04066 1/20 0.49
EPHX1 P07099 1/20 0.48
CA3 P07451 2/20 0.47
CA5A P35218 2/20 0.47
CA5B Q9Y2D0 2/20 0.47
CA12 O43570 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
TSHR P16473 2/20 0.46
ALDH1A1 P00352 1/20 0.46
FAAH O00519 8/20 0.45
ALOX15 P16050 1/20 0.45
CES1 P23141 5/20 0.43
CES2 O00748 3/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7710932 0.91 TSHR (0.58) FUCA1EPHX1CA3CA5ACA5B
SCHEMBL28841616 0.87 TSHR (0.42) FUCA1EPHX1CA3CA5ACA5B
Trifluoroacetic Acid SCHEMBL5344960 0.86 PAOX (0.45) FUCA1EPHX1CA3CA5ACA5B
Trifluoroacetic Acid SCHEMBL8529050 0.84 FUCA1 (0.47) FUCA1EPHX1FAAHALOX15CES1
Trifluoroacetic Acid SCHEMBL7024064 0.84 FUCA1 (0.47) FUCA1EPHX1FAAHALOX15CES1
Trifluoroacetic Acid SCHEMBL10701644 0.84 EPHX1 (0.56) EPHX1TSHRALDH1A1FAAHCES1
Trifluoroacetic Acid SCHEMBL29581339 0.83 FAAH (0.54) EPHX1FAAHCES1CES2MEN1
Bicarbonate SCHEMBL910039 0.83 TSHR (0.58) EPHX1TSHRALDH1A1ALOX15MEN1
Bicarbonate SCHEMBL28699185 0.83 TSHR (0.58) EPHX1TSHRALDH1A1ALOX15MEN1
Trifluoroacetic Acid SCHEMBL3273685 0.83 FAAH (0.61) EPHX1TSHRALDH1A1FAAHCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118763275-A Lithium ion battery electrolyte and preparation method thereof 合肥乾锐科技有限公司 2024-10-11 CN claimed
CN-114805289-B Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound 昆明理工大学 2024-05-28 CN claimed
CN-114805289-A Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound 昆明理工大学 2022-07-29 CN claimed
CN-118763275-A Lithium ion battery electrolyte and preparation method thereof 合肥乾锐科技有限公司 2024-10-11 CN disclosed
CN-118763275-A Lithium ion battery electrolyte and preparation method thereof 合肥乾锐科技有限公司 2024-10-11 CN disclosed
CN-114805289-B Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound 昆明理工大学 2024-05-28 CN disclosed
CN-117015282-A Method for optimizing perovskite film, perovskite film obtained by method and application of perovskite film 极电光能有限公司 2023-11-07 CN disclosed
CN-115494167-A Method for realizing co-outflow of phosphorothioate oligonucleotide isomers in chromatographic analysis 南京金斯瑞生物科技有限公司 2022-12-20 CN disclosed
CN-114805289-A Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound 昆明理工大学 2022-07-29 CN disclosed
EP-1809300-A4 METHOD FOR TREATING BACTERIAL INFECTIONS IN HORSES OR PIGS WITH TILMICOSIN IDEXX LAB INC (US) 2009-03-25 EP disclosed
US-7282487-B2 Method for treating bacterial infections in horses or pigs with tilmicosin IDEXX LABORATORIES (US) 2007-10-16 US disclosed
EP-1809300-A1 METHOD FOR TREATING BACTERIAL INFECTIONS IN HORSES OR PIGS WITH TILMICOSIN IDEXX Laboratories Inc (US) 2007-07-25 EP disclosed
WO-2006049739-A1 METHOD FOR TREATING BACTERIAL INFECTIONS IN HORSES OR PIGS WITH TILMICOSIN IDEXX LABORATORIES, INC. (US) 2006-05-11 WO disclosed
US-20060094669-A1 Salts of lipophilic acids, such as fatty acids, diacids, polycarboxylic acids and aromatic acids in a pharmaceutically acceptable solvent to form an injectable composition that precipitates when injected into water; improved pharmacokinetics IDEXX LABORATORIES 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094669-A1 Salts of lipophilic acids, such as fatty acids, diacids, polycarboxylic acids and aromatic acids in a pharmaceutically acceptable solvent to form an injectable composition that precipitates when injected into water; improved pharmacokinetics NRDC, PIGS, PPARD FUCA1 1818/4885EPHX1 3058/4885CA3 1141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.